Evidence map›Paper›PMID 25857620›Full record

ReviewBiochimica et biophysica acta2015

Future perspectives: Moving towards NCL treatments.

Susan L Cotman, Sara E Mole, Romina Kohan

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biochimica et biophysica acta, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 3 countries.

Susan L CotmanCenter for Human Genetic Research and Department of Neurology, Harvard Medical School, Massachusetts General Hospital, 185 Cambridge Street, Boston, MA 02114, USA. Electronic address: cotman@helix.mgh.harvard.edu.
Sara E MoleMRC Laboratory for Cell Biology, Department of Genetics, Evolution & Environment, UCL Institute of Child Health, University College London, Gower St, London, WC1E 6BT, UK.
Romina KohanCentro de Estudio de las Metabolopatías Congénitas (CEMECO), Facultad de Ciencias Médicas, Universidad Nacional de Córdoba. Ferroviarios 1250, (5014) Córdoba, Argentina.
Harvard University · USMRC Laboratory for Molecular Cell Biology · GBUniversidad Nacional de Córdoba · AR

Funding

Endocytosis in JNCLR01NS073813 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI COTMAN, SUSAN LYNN · 2011 to 2015
$1.8M
NINDS NIH HHS R01 NS073813
6 · The paper itself

Abstract

Clinicians, basic researchers, representatives from pharma and families from around the world met in Cordoba, Argentina in October, 2014 to discuss recent research progress at the 14th International Congress on Neuronal Ceroid Lipofuscinoses (NCLs; Batten disease), a group of clinically overlapping fatal, inherited lysosomal disorders with primarily neurodegenerative symptoms. This brief review article will provide perspectives on the anticipated future directions of NCL basic and clinical research as we move towards improved diagnosis, care and treatment of NCL patients. This article is part of a Special Issue entitled: Current Research on the Neuronal Ceroid Lipofuscinoses (Batten Disease).

Indexed as

Batten diseaseNeuronal Ceroid Lipofuscinosis (NCL)

Identifiers

PMID25857620
PMCPMC4567439
OpenAlexW1978052369

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.